ABSTRACT
BACKGROUND: Enfortumab vedotin (EV) is an antibody-drug conjugate directed against Nectin-4 that is used to treat urothelial carcinoma. Nectin-4 is inherently expressed in the skin and adnexal structures. Since therapeutic options for cutaneous adnexal carcinomas are limited, we sought to evaluate Nectin-4 expression in adnexal carcinomas and benign adnexal neoplasms to identify tumors that are potentially targetable with EV. METHODS: Eight sebaceous carcinomas (seven periocular and one lymph node metastasis), eight digital papillary adenocarcinomas, seven squamoid eccrine ductal carcinomas, eight poromas, eight trichilemmomas, and seven sebaceous adenomas were subjected to immunohistochemical staining for anti-Nectin-4 antibody. H-scores for Nectin-4 expression were calculated. RESULTS: Benign adnexal neoplasms had a significantly lower mean (±SD) Nectin-4 H-score (142.6 ± 39.1) than did the adnexal carcinomas (198 ± 90.8; p = 0.006). Nectin-4 was expressed in 91% (21/23) of adnexal carcinomas. Sebaceous carcinomas frequently exhibited high expression of Nectin-4 (88% [7/8]), with a mean (±SD) H-score (258.1 ± 58.4) significantly higher than those for digital papillary adenocarcinomas (197.5 ± 52.5; p = 0.035) and squamoid eccrine ductal carcinomas (131.4 ± 114.1; p = 0.031). Sebaceous carcinomas also had significantly higher H-scores than did sebaceous adenomas (186.4 ± 25.0; p = 0.013). CONCLUSIONS: Increased Nectin-4 expression in a subset of cutaneous adnexal carcinomas, particularly sebaceous carcinomas, reveals that EV is a potential therapeutic option for these tumors.
Subject(s)
Adenocarcinoma, Papillary , Antibodies, Monoclonal , Nectins , Neoplasms, Adnexal and Skin Appendage , Skin Neoplasms , Humans , Adenoma , Carcinoma, Ductal , Carcinoma, Skin Appendage , Carcinoma, Transitional Cell , Neoplasms, Adnexal and Skin Appendage/drug therapy , Sebaceous Gland Neoplasms/pathology , Skin Neoplasms/pathology , Sweat Gland Neoplasms/drug therapySubject(s)
Adenocarcinoma/drug therapy , Immune Checkpoint Inhibitors/therapeutic use , Immunotherapy/methods , Lung Neoplasms/drug therapy , Neoplasm Metastasis/drug therapy , Neoplasms, Adnexal and Skin Appendage/drug therapy , Adenocarcinoma/diagnosis , Adenocarcinoma/pathology , Antibodies, Monoclonal, Humanized/therapeutic use , Humans , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Metastasis/diagnostic imaging , Neoplasm Metastasis/pathology , Neoplasms, Adnexal and Skin Appendage/diagnosis , Neoplasms, Adnexal and Skin Appendage/pathology , Tomography, X-Ray ComputedABSTRACT
INTRODUCTION: Malignant cutaneous epithelial tumors comprise various skin malignancies originating from the cutaneous epithelium, including cutaneous squamous cell carcinoma, basal cell carcinoma, and malignant cutaneous adnexal tumors. Treatment options are limited, as the rarity of these tumors, especially among Asians, renders well-controlled clinical trials extremely challenging to conduct. Thus, we designed a clinical trial to evaluate the efficacy and safety of the anti-programmed cell death-1 (PD-1) monoclonal antibody nivolumab in patients with metastatic cutaneous squamous cell carcinomas and other rare metastatic cutaneous epithelial tumors. METHODS AND ANALYSIS: This is an open-label, single-arm, multicenter, phase 2 clinical trial involving patients with metastatic malignant cutaneous epithelial tumors. Nivolumab (480âmg) will be administered intravenously every 4 weeks for a maximum of 26 doses. The primary outcome of the study will be the response rate based on response evaluation criteria in solid tumors, version 1.1. Assuming a null hypothesis of a response rate ≤5% and an alternative hypothesis of a 25% response rate, a minimum of 26 patients are required to achieve a 5% two-sided type I error and 80% power based on the exact binomial distribution. Finally, a target cohort size of 30 patients was determined as some patient dropout will be expected. DISCUSSION: This is the first phase 2 clinical trial evaluating the efficacy and safety of the PD-1 inhibitor nivolumab in Asian patients with metastatic malignant cutaneous epithelial tumors. The findings of the study will contribute to the development of novel treatment approaches for patients with rare cutaneous malignancies, which remains an unmet clinical need. TRIAL REGISTRATION: Registry number: jRCT 2031190048.
Subject(s)
Carcinoma, Basal Cell/drug therapy , Carcinoma, Squamous Cell/drug therapy , Neoplasms, Adnexal and Skin Appendage/drug therapy , Nivolumab , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Skin Neoplasms/drug therapy , Adult , Antineoplastic Agents, Immunological/administration & dosage , Antineoplastic Agents, Immunological/adverse effects , Carcinoma, Basal Cell/pathology , Carcinoma, Squamous Cell/pathology , Epithelial Cells/drug effects , Epithelial Cells/pathology , Female , Humans , Japan , Male , Neoplasm Staging , Neoplasms, Adnexal and Skin Appendage/pathology , Nivolumab/administration & dosage , Nivolumab/adverse effects , Response Evaluation Criteria in Solid Tumors , Skin Neoplasms/pathologyABSTRACT
Skin adnexal cancers (SAC) are a heterogeneous group of rare malignancies with histological differentiation towards epithelial adnexa, which lack effective systemic treatments. The aim of this work is to identify any potentially druggable genomic alterations for possible targeted therapies. Cases of primary or recurrent/metastatic (RM) SAC between 2002 and 2014 were identified by searching the institutional cancer registration database. Histological sections of all referral cases were reviewed by a dedicated pathologist to confirm diagnosis. Immunohistochemistry was performed to assess the expression of androgen receptors (AR) and human epidermal growth factor receptor type 2 (HER2). Targeted next-generation sequencing (T-NGS) was performed to identify targetable mutations (panel of 50 genes analyzed by Cancer Hotspot Panel, Ion-Torrent Personal Genome Machine). Mutational analysis of the PTCH1 gene not present in the T-NGS panel was assessed by Sanger sequencing. A total of 45 cases with available histological samples were identified (35 primary, 10 RM). The most frequent histological type was porocarcinoma (n = 12). Globally, 14 cases (31%) were AR+ (6/10 RM, 60%; 8/35 primary, 23%). HER2 was shown as 2+ in eight of 42 (19%) cases (2/9 RM, 22%; 6/33 primary, 18%). DNA was adequate for T-NGS analysis in 25 cases. In the majority of cases (17 cases, 68%) at least one mutation in oncogenes or tumor suppressor genes was found: the most frequent ones involved TP.53 (13 cases, 76% of mutated SAC) and PIK3CA (three cases, 18%). The rate of PTCH1 mutation was 30%. These findings support the use of molecular screening in patients with advanced SAC.
Subject(s)
Biomarkers, Tumor/genetics , Neoplasm Recurrence, Local/genetics , Neoplasms, Adnexal and Skin Appendage/genetics , Sebaceous Gland Neoplasms/genetics , Sweat Gland Neoplasms/genetics , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Biomarkers, Tumor/antagonists & inhibitors , Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors , Class I Phosphatidylinositol 3-Kinases/genetics , DNA Mutational Analysis , Female , High-Throughput Nucleotide Sequencing , Humans , Male , Molecular Targeted Therapy/methods , Mutation , Mutation Rate , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/prevention & control , Neoplasms, Adnexal and Skin Appendage/drug therapy , Neoplasms, Adnexal and Skin Appendage/pathology , Patched-1 Receptor/antagonists & inhibitors , Patched-1 Receptor/genetics , Receptor, ErbB-2/antagonists & inhibitors , Receptor, ErbB-2/genetics , Retrospective Studies , Sebaceous Gland Neoplasms/drug therapy , Sebaceous Gland Neoplasms/pathology , Sweat Gland Neoplasms/drug therapy , Sweat Gland Neoplasms/pathology , Tumor Suppressor Protein p53/antagonists & inhibitors , Tumor Suppressor Protein p53/geneticsSubject(s)
Isotretinoin/therapeutic use , Neoplasms, Adnexal and Skin Appendage/pathology , Skin Neoplasms/pathology , Syringoma/pathology , Administration, Topical , Aged , Biopsy, Needle , Diagnosis, Differential , Female , Follow-Up Studies , Forehead , Humans , Immunohistochemistry , Neoplasms, Adnexal and Skin Appendage/diagnosis , Neoplasms, Adnexal and Skin Appendage/drug therapy , Rare Diseases , Skin Neoplasms/diagnosis , Skin Neoplasms/drug therapy , Syringoma/diagnosis , Treatment OutcomeABSTRACT
Ocular adnexal lymphoma (OAL) has been associated with Chlamydophila psittaci infection, for which doxycycline has been suggested as a treatment option. We conducted this study to evaluate the long-term results of first-line doxycycline treatment in patients with OAL. Ninety patients with histologically confirmed OAL with marginal zone B cell lymphoma were enrolled. Each patient received one or two cycles of doxycycline (100 mg bid) for 3 weeks. After a median follow-up period of 40.5 months (8-85), the 5-year progression-free survival (PFS) rate was 60.9 %. All patients were alive at the last follow-up date. Thirty-one patients (34 %) showed local treatment failure without systemic spread. However, PFS rate in these patients was 100 % after salvage chemotherapy and/or radiotherapy. PFS was independently predicted in multivariate analysis by the tumor-node-metastasis (TNM) staging (hazard ratio [HR], 4.35; 95 % confidence interval [CI], 2.03-9.32; P < 0.001) and number of cycles of doxycycline (HR, 0.31; 95 % CI, 0.14-0.69; P = 0.004). No serious adverse event was reported during doxycycline therapy. In conclusion, first-line doxycycline therapy was effective and safe. Patients who failed to respond to doxycycline therapy were successfully salvaged with chemotherapy and/or radiotherapy without compromising long-term outcomes. Patients with T1N0M0 disease could be considered good candidates for first-line doxycycline.
Subject(s)
Doxycycline/therapeutic use , Eye Neoplasms/drug therapy , Lymphoma, B-Cell, Marginal Zone/drug therapy , Neoplasms, Adnexal and Skin Appendage/drug therapy , Adult , Aged , Disease-Free Survival , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neoadjuvant Therapy , Treatment Outcome , Young AdultABSTRACT
Malignant skin adnexal tumors are rare neoplasms which are derived from adnexal epithelial structures of the skin: hair follicle, or sebaceous, apocrine or eccrine glands. Among them, eccrine porocarcinoma is the most frequent, with an aggressive behavior compared to other more common forms of non-melanoma skin cancer. Only few reports describe the treatment of metastatic adnexal tumors, and there is no consensus about the better strategy of chemotherapy. Given the few cases and the absence of randomized clinical trials, it is important to collect clinical experiences on these tumors. Most of these adenocarcinomas are very aggressive and also chemoresistant, and only a targeted-therapy could have an impact on patient survival. Therefore, further studies on the biology of these diseases are necessary. The purpose of the present review is to discuss the treatment of malignant neoplasms of cutaneous adnexae and to suggest some future therapeutic options based on targeted-therapy.
Subject(s)
Antineoplastic Agents/therapeutic use , Neoplasms, Adnexal and Skin Appendage/drug therapy , Combined Modality Therapy , Humans , Neoplasms, Adnexal and Skin Appendage/diagnosis , Neoplasms, Adnexal and Skin Appendage/therapyABSTRACT
Extranodal marginal zone lymphoma (MZL) of mucosa-associated lymphoid tissue usually originates from cutaneous or mucosal surfaces. A rare site of involvement is the subcutaneous tissue of any location. Here, we describe a 58-year-old man who presented with bilateral extranodal MZL of mucosa-associated lymphoid tissue from ocular adnexae that involved subcutaneous tissue and subsequently extended to multiple anatomical locations in the head and neck, upper back, and arm. The neoplastic cells expressed B-cell markers, and the plasma cells expressed IgG4. The unusual pattern of infiltration of this extranodal MZL and the possible significance of IgG4 expression in this case are discussed.
Subject(s)
Eye Neoplasms/pathology , Lymphoma, B-Cell, Marginal Zone/pathology , Neoplasms, Adnexal and Skin Appendage/secondary , Subcutaneous Tissue/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/analysis , Biopsy , Eye Neoplasms/chemistry , Eye Neoplasms/drug therapy , Eye Neoplasms/immunology , Humans , Immunoglobulin G/analysis , Immunohistochemistry , Lymphoma, B-Cell, Marginal Zone/chemistry , Lymphoma, B-Cell, Marginal Zone/drug therapy , Lymphoma, B-Cell, Marginal Zone/immunology , Male , Middle Aged , Neoplasm Staging , Neoplasms, Adnexal and Skin Appendage/chemistry , Neoplasms, Adnexal and Skin Appendage/drug therapy , Neoplasms, Adnexal and Skin Appendage/immunology , Subcutaneous Tissue/chemistry , Subcutaneous Tissue/immunology , Treatment OutcomeABSTRACT
Cancers derived from anogenital mammary-like glands are rare, and their identification and selection of treatment for dissemination may be difficult. We encountered two such tumors, which both presented as occult primaries with nodal and hematogenous metastases. They were studied by immunohistochemistry, HER2 receptor assay, and gene expression profiling. Both tumors had some microscopical and immunohistochemical features in common with breast cancer, but lacked estrogen and progesterone receptors. Taxane-platinum-based systemic chemotherapy did not stop progression in a male patient, in whom a developing inguinal skin lesion was the likely primary tumor. The same regimen gave partial remission in a later, female, patient. After the mammary-like, HER2 positive nature of her tumor was confirmed by gene expression profiling using CupPrint and TargetPrint assays, treatment with vinorelbine-trastuzumab induced complete remission that is maintained by trastuzumab alone for almost 4 years after initial diagnosis. Molecular and immunohistochemical characterization of these rare tumors may identify them and sometimes guide systemic chemotherapy away from a non-specific and "broad spectrum" regimen toward a targeted therapy, resulting in greater effectiveness with less side effects.
Subject(s)
Gene Expression Profiling , Lymphatic Metastasis/pathology , Neoplasms, Adnexal and Skin Appendage/diagnosis , Neoplasms, Unknown Primary/diagnosis , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/drug therapy , Bone Neoplasms/secondary , Female , Groin/pathology , Humans , Male , Middle Aged , Neoplasms, Adnexal and Skin Appendage/drug therapy , Neoplasms, Adnexal and Skin Appendage/genetics , Neoplasms, Unknown Primary/drug therapy , Neoplasms, Unknown Primary/genetics , Receptor, ErbB-2/geneticsABSTRACT
PURPOSE: To describe a case of adnexal Kaposi's sarcoma successfully treated with intralesional interferon alpha 2b injections. METHODS: Case Report. RESULTS: A 31 year old black Haitian male presents with severe nodular induration and erythema of both eyelids with hemorrhagic infiltration of the bulbar and palpebral conjunctivae, advanced on the right. Clinical, histological, and immunohistochemical examination yielded the diagnosis of Kaposi's sarcoma. The patient was subsequently diagnosed with AIDS, started on highly active anti-retroviral therapy (HAART) and systemic doxorubicin, and initially received topical 3 million IU per mL of interferon alpha-2b eyedrops (Intron-A(R), Schering Corporation, Kenilworth, NJ) every 6 hours to the right eye for 9 weeks. This systemic therapy resulted in minimal clinical response with a CD4 count increase from 12 to 61 cells per microliter. Progressive entropion and corneal compromise on the right prompted a trial of intralesional injections of interferon alpha-2b. Over a 4 week period, 3 injections (3 million IU in 0.5mL, 1.5 million IU in 0.5mL, and 1.5 million IU in 0.5mL) were given. This resulted in a dramatic reduction in tumor burden and lid edema, an improvement in lid position, and corneal healing. CONCLUSION: Ocular adnexal and conjunctival Kaposi's sarcoma was successfully treated with 3 adjuvant intralesional interferon alpha-2b injections leading to a dramatic decrease in tumor mass.